| Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine A Sarayani, B Cicali, CH Henriksen, JD Brown Research in Social and Administrative Pharmacy 17 (2), 483-486, 2021 | 75 | 2021 |
| A valid warning or clinical lore: an evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort TW Ackley, D McManus, JE Topal, B Cicali, S Shah Antimicrobial agents and chemotherapy 65 (2), 10.1128/aac. 02290-20, 2021 | 64 | 2021 |
| Risk assessment of drug‐induced long QT syndrome for some COVID‐19 repurposed drugs V Michaud, P Dow, SB Al Rihani, M Deodhar, M Arwood, B Cicali, ... Clinical and Translational Science 14 (1), 20-28, 2021 | 49 | 2021 |
| Reproducibility of quantitative systems pharmacology models: current challenges and future opportunities DC Kirouac, B Cicali, S Schmidt CPT: pharmacometrics & systems pharmacology 8 (4), 205-210, 2019 | 35 | 2019 |
| Application of a novel medication-related risk stratification strategy to a self-funded employer population B Cicali Benefits Quarterly 34 (2), 49-55, 2018 | 14 | 2018 |
| Syntheses and analytical characterizations of N‐alkyl‐arylcyclohexylamines J Wallach, T Colestock, B Cicali, SP Elliott, PV Kavanagh, A Adejare, ... Drug Testing and Analysis 8 (8), 801-815, 2016 | 12 | 2016 |
| Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis JD Brown, B Cicali, C Henriksen, I Malaty, MS Okun, MJ Armstrong Journal of Managed Care & Specialty Pharmacy 27 (6), 785-790, 2021 | 11 | 2021 |
| Comparison of contraceptive failures associated with CYP3A4-inducing drug-drug interactions by route of hormonal contraceptive in an adverse event reporting system T Sunaga, B Cicali, S Schmidt, J Brown Contraception 103 (4), 222-224, 2021 | 11 | 2021 |
| Quantitative assessment of levonorgestrel binding partner interplay and drug‐drug interactions using physiologically based pharmacokinetic modeling B Cicali, K Lingineni, R Cristofoletti, T Wendl, J Hoechel, H Wiesinger, ... CPT: Pharmacometrics & Systems Pharmacology 10 (1), 48-58, 2021 | 11 | 2021 |
| Risk of drug-induced Long QT Syndrome associated with the use of repurposed COVID-19 drugs: A systematic review V Michaud, P Dow, SBA Rihani, M Deodhar, M Arwood, B Cicali, ... MedRxiv, 2020.04. 21.20066761, 2020 | 11 | 2020 |
| A pharmacoepidemiologic approach to evaluate real-world effectiveness of hormonal contraceptives in the presence of drug–drug interactions A Sarayani, JD Brown, AJ Goodin, P Squires, P Pham, B Cicali, ... Epidemiology 32 (2), 268-276, 2021 | 10 | 2021 |
| Physiologically based pharmacokinetic modeling to assess the impact of CYP2D6‐mediated drug‐drug interactions on tramadol and O‐desmethyltramadol exposures via allosteric and … T Long, R Cristofoletti, B Cicali, V Michaud, P Dow, J Turgeon, S Schmidt The Journal of Clinical Pharmacology 62 (1), 76-86, 2022 | 9 | 2022 |
| Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: physiologically‐based modeling as a candle in the dark B Cicali, T Long, S Kim, R Cristofoletti British Journal of Clinical Pharmacology 86 (11), 2247-2255, 2020 | 7 | 2020 |
| Determining the exposure threshold for levonorgestrel efficacy using an integrated model based meta‐analysis approach K Lingineni, A Chaturvedula, B Cicali, R Cristofoletti, T Wendl, J Hoechel, ... Clinical Pharmacology & Therapeutics 111 (2), 509-518, 2022 | 5 | 2022 |
| Use of drug claims data and a medication risk score to assess the impact of CYP2D6 drug interactions among opioid users on healthcare costs V Michaud, R Bikmetov, MK Smith, P Dow, LI Darakjian, M Deodhar, ... Journal of Personalized Medicine 11 (11), 1174, 2021 | 5 | 2021 |
| Breaking the rules for studies using real-world observational data: the case of direct-acting anticoagulants and antiepileptic drugs J Brown, B Cicali, P Pham, S Schmidt, GYH Lip European Heart Journal-Cardiovascular Pharmacotherapy 6 (3), 155-156, 2020 | 4 | 2020 |
| Population-based medication risk stratification and personalized medication risk score J Turgeon, V Michaud, B Cicali US Patent 11,361,856, 2022 | 3 | 2022 |
| Development of a Translational Exposure‐Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products B Cicali, L Da Silva, A Sarayani, K Lingineni, M Pressly, S Kim, T Wendl, ... Clinical Pharmacology & Therapeutics 112 (4), 909-916, 2022 | 2 | 2022 |
| YEARLY MEDICAL EXPENDITURE IN PATIENTS TREATED WITH CYP2D6-DEPENDENT OPIOIDS AND IMPACT OF CONCOMITANT TREATMENT WITH CYP2D6 SUBSTRATE OR INHIBITOR DRUGS. V Michaud, B Cicali, J Verzicco, CH Knowlton, J Turgeon CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S80-S80, 2018 | 2 | 2018 |
| INCREASED RISK OF MEDICATION-RELATED PROBLEMS DUE TO CONCOMITANT ADMINISTRATION OF CYP2D6-DEPENDENT OPIOIDS AND CYP2D6 INTERACTING DRUGS. B Cicali, J Turgeon, J Verzicco, CH Knowlton, V Michaud CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S63-S63, 2018 | 2 | 2018 |
